The Effects of BCRP Q141K on Allopurinol Pharmacokinetics and Dynamics

a study on Chronic Gout Hyperuricemia

Summary

for people ages 18–40 (full criteria)
healthy people welcome
at Mountain View, California
study started

Description

Summary

Subjects will undergo a placebo and allopurinol phase to better understand the effects of the reduced function BCRP Q141K variant on allopurinol pharmacokinetics and pharmacodynamics.

Keywords

Chronic Gout Hyperuricemia allopurinol

Eligibility

You can join if…

Open to people ages 18–40

  • self-identified as Asian/European ancestry
  • generally healthy with approved lab values for CBC,HFP,RFP, and uric acid
  • Subjects with the ABCG2 genotype, homozygous, heterozygous or homozygous for the major allele of rs2231142 will be recruited

You CAN'T join if...

  • vascular disease
  • renal impairment
  • medications/supplements that affect uric acid levels
  • pregnant or lactating women
  • prior history of allergic reaction to allopurinol or testing positive for HLA-B*5801 allele
  • risk of urinary or gastric retention or narrow-angle glaucoma
  • impaired hepatic function
  • evidence of anemia
  • evidence or diagnosis of congestive heart failure
  • smokers
  • subjects with a mutation other than rs2231142 in the ABCG2 genotype
  • subjects taking hormonal contraceptives or other hormonal medications
  • evidence of recreational drug use as determined by questionnaire

Location

  • Open Medicine Institute accepting new patients
    Mountain View, California, 94040, United States

Details

Status
accepting new patients
Start Date
Sponsor
University of California, San Francisco
ID
NCT02956278
Phase
Phase 4
Lead Scientist
Kathleen Giacomini
Study Type
Interventional
Last Updated
October 30, 2017
I’m interested in this study!

© The Regents of the University of California